... Novel Agents for cHL: Operating Instructions

Il ruolo del brentuximab vedotin nel linfoma di Hodgkin in prima linea e nel paziente ricaduto/refrattario

#### **Antonello Pinto**


Hematology-Oncology and Stem Cell Transplantation Unit Department of Hematology & Developmental Therapeutics

National Cancer Institute, Fondazione G. Pascale, IRCCS, Naples, Italy





Como 23 DC – C. di Stabia 79 DC



#### Antibody drug conjugates: ...how the story began...



#### C. PLINII SECUNDI NATURALIS HISTORIÆ,

#### TONUS PRIMUS.

Com Consecutio & sinortioniber Haaseaa ar Barrath, Pisyasye, Romane, Galamat, Dargersonyu, Scalavan, Salawan, Ja, Yamu, & Varana,

Accessor preverse travia Ladicare on MUL, complexion of many Explorem access or indicate.

hom June Fu, Guanara v St. Monores Liber Singulata al Bluthane Virent Johannes Capitanas.



Arrienters } Aged HACK105, Av. 1669



PLINY THE ELDER Natural History : A Selection



#### Como 23 DC – C. di Stabia 79 DC

Aquatilium secuntur in medicina beneficia, opifice natura ne in illis quidem cessante et per undas fluctusque...

Seguono í benefící nella medícína deglí esserí acquatící, con la natura artefíce... e che esercíta le ínstancabílí forze attraverso onde e fluttí .... ... The great Roman natural scientist Gaius Plinius Secundus (Pliny the Elder) in his comprehensive study (4) of about 60 A.D. first described a most potent Indian Ocean sea hare<sup>1</sup> of the genus *Dolatells*. Extracts from this animal and two related *Aplysia* species from the Mediterranean were well known for their toxic properties during the reign of Nero (4, 5). By 150 A.D. Nicander (5) recognized the possibility of using such extracts for treatment of certain diseases. However, the potential of the Indian Ocean *Dolatella* with respect to modern medical problems was not recognized until we uncovered evidence for extremely active anticancer constituents in the Indian Ocean *Dolatella auricularia*<sup>1</sup> (3c).

We have now completed the isolation and preliminary characterization of an exceptionally promising series of cancer chemotherapeutic agents designated dolastatins 1-9 from *D. auricularia*. The dolastatins most probably correspond to the potent *D. auricularia* constituents recognized from ancient to fairly recent (7) times. Since dolastatin 1 has been shown (by the U.S. National Cancer

"The present contribution is part 72 is the series Antineoplastic Agents. For part 71 refer to (1).


"The Romans first designated Mollosca of the family Aplysiidae in this fashion due to a similarity between the ears of a hare and the suriculate tentacles of these gastropods, consolt (5).

"The D. assiculatio was probably that first described by Pliny and the minor variations recorded in subsequent literature as, e.g., D. andersoni, D. adifornios, D. econdete, and D. acquals are actually one species, namely D. cariculatis, see (6).

# Brentuximab Vedotin: ...CD30...HL...and beyond...


Auristatins (Tubulin polymerase inhibitor)

# The Auristatins




- A. The parent antitubulin agent Dolastatin 10 isolated from the Indian ocean sea hare Dolabella ariculara (shown in B)
- C. The synthetic Dolastatin 10 analogues monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF) are used as payloads for ADCs.

## Brentuximab Vedotin: ...CD30...HL...and beyond...



In addition to BV's primary MOA non-clinical studies highlight other contributory mechanisms of action, including :

- Antibody dependent phagocytosis (ADCP)
- Bystander effects on nearby cells in the tumor microenvironment due to released MMAE
- Immunogenic cell death (ICD) due to endoplasmic reticulum (ER) stress that drives exposure of immune-activating molecules



Clinical Cancer


Research

#### Cancer Therapy: Preclinical

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate


Nicole M. Okeley, Jamie B. Miyamoto, Xinqun Zhang, Russell J. Sanderson, Dennis R. Benjamin, Eric L. Sievers, Peter D. Senter, and Stephen C. Alley


## Brentuximab Vedotin: ...killing Of CD30-negative targets




### ... Novel Agents for cHL: Brentuximab VEDOTIN


### The MMAE payload is extruded via MDR proteins






Phase 1 trial of BV+cyclosporine in BV-refractory HL







N = 14 ORR 75% CR 42%


Moderate † in toxicity compared to BV alone


Chen R, et al. ASH 2018 Chen R. et al. Molecular Cancer Therapeutics OnlineFirst on April 3, 2015

# Hodgkin Lymphoma: ...Update 2019...

# Phase I Brentuximab Vedotin in Relapsed HL

- 21-year-old female
- HL diagnosed 2003
  - ABVD + XRT to mediastinum
  - ICE
  - BEAM→ASCT
  - HDAC-inhibitor
- SGN-35 2.7 mg/kg x 8 cycles
  - Best clinical response: CR
  - CT 93% reduction, PET-
  - PET negative






# Single agent after ASCT failure

- Registration studies
- Post-Registration (real-life) studies
- Sequential single agent BV and chemotherapy
  - (...on demand strategy...) **ASCT-eligible/ineligible** 
    - BV alone (about 30-35% of pts. achieve a metabolic CR)
    - BV <mCR: ICE, DICE, IGEV, GVD, GDP
    - BV and Bendamustine or Bendamustine and BV


# Incorporate BV into salvage

- Bendamustine BV (BBV)
- Gemcitabine BV
- BV-DHAP (Brave)
- BV-ESHAP (BrESHAP)
- BV-ICE
- BV for 'chemo-free' salvage
  - BV+CPIs

# Phase II pivotal study of brentuximab vedotin in relapsed HL post ASCT



94% patients achieved tumour reduction



Chen et al., Blood 2016

www.anpactjournals.com/oncetarget/ Oncotarget, 2017, Vol. 8, (No. 53), pp: 91703-91710

**Clinical Research Paper** 

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

Cinzia Pellegrini<sup>1,7</sup>, Alessandro Broccoli<sup>1,7</sup>, Alessandro Pulsoni<sup>2</sup>, Luigi Rigacci<sup>2</sup>, Caterina Patti<sup>4</sup>, Guido Gini<sup>5</sup>, Donato Mannina<sup>8</sup>, Monica Tani<sup>7</sup>, Chiara Rusconi<sup>8</sup>, Alessandra Romano<sup>8</sup>, Anna Vanazzi<sup>28</sup>, Barbara Botto<sup>11</sup>, Armando Santoro<sup>12</sup>, Stefan Hoaus<sup>10</sup>, Gian Matteo Rigolin<sup>14</sup>, Pellegrino Musto<sup>15</sup>, Patrizio Mazza<sup>16</sup>, Stefano Molica<sup>17</sup>, Paolo Corradini<sup>18</sup>, Angelo Fama<sup>18</sup>, Francesco Gaudio<sup>28</sup>, Michele Merli<sup>21</sup>, Fioravante Ronconi<sup>22</sup>, Giuseppe Gritti<sup>21</sup>, Daniele Vallisa<sup>24</sup>, Patrizia Tosi<sup>26</sup>, Anna Marina Liberati<sup>24</sup>, Antonello Pinto<sup>27</sup>, Vincenzo Pavone<sup>28</sup>, Filippo Gherlinzoni<sup>28</sup>, Maria Paola Bianchi<sup>26</sup>, Stefano Volpetti<sup>18</sup>, Livio Trentin<sup>28</sup>, Maria Cecilia Goldaniga<sup>31</sup>, Maurizio Bonfichi<sup>24</sup>, Amalia De Renzo<sup>35</sup>, Corrado Schiavotto<sup>36</sup>, Michele Spina<sup>37</sup>, Angelo Michele Carella<sup>36</sup>, Vittorio Stefoni<sup>1</sup>, Lisa Argnani<sup>1</sup> and Pier Luigi Zinzani<sup>2</sup>





Figure 4: Progression free survival in patients with and without stem cell transplant (SCT) consolidation.



### ... Novel Agents for cHL: Operating Instructions




Table 1. Patients' demographics and disease characteristics (n = 30)

Characteristic	Data
Age, years, mean ± SD, median	30.9 ± 12.8, 27
Sex, male/female, n	13/17
Stage, n (%)	
II.	13 (43.3)
III-IV	17 (56.7)
Primary refractory disease, n (%)	21 (70.0)
Regimens prior to BV, median no.	3 (range, 2-11)
First salvage treatment, n	
Ifosfamide-containing regimen	17
Cytarabine- and platinum-containing regimen	9
BEACOPP regimen	4
BV cycles, median no.	4 (range, 2-8)

# Oncologist

tematologic Malgnancies

#### Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

Per Linis Zecon," Codo Priziere," More Contorn', "Automore RL' Antonico Perto," Mechae Parene," Line Beacc." Microso Cell, "Automore Broccol, "Line Antonin," Automore Priziere"

	Outcomes
BV	4 (r 2-8)
ORR	12/30 (40%)
CR @ PET4 (5PDS : ≤ 2)	9 (30%)
PR @ PET4	3 (10%)
ASCT	9 (CR) + 5 (PR/NR)
ASCT outcome @ 18 mo.s	Post-BV CR 8/9 -+ cCR Post-BV NR 1/5 -+ cCR

The Oncologist 2015;20:1-4


# Phase IV study: Brentuximab vedotin in patients with R/R HL ineligible for SCT or multi-agent chemotherapy (NCT01990534)

Walewski J, et al. ISHL 2016, Poster presentation #P104

Response:


	ITT population (N=60)		
	Per IRF	Per INV	
ORR (CR+PR), n (%) [95% CI]	30 (50) [37-63]	29 (48) [35-62]	
Best clinical response, n (%) [95% CI] CR PR	7 (12) [5-23] 23 (38) [26-52]	9 (15) [7-27] 20 (33) [22-47]	
Median time to response, weeks (range) Time to response (CR+PR) Time to best response Time to CR Time to CR	6.0 (5-39) 11.2 (5-60) 12.0 (6-60) 6.0 (5-39)	6.1 (5-53) 11.8 (5-53) 12.1 (11-29) 9.1 (5-53)	

Median PFS (per IRF) 4.8 mos (95% CI: 2.96–5.32); median OS NE




# Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS

Miriam Marangon, Lisa Argnani, Alessandro Re, Arben Lleshi, Maurizio Bonfichi, Antonello Pinto, Nicola Bianchetti, Cinzia Pellegrini, Vittorio Stefoni and Pier Luigi Zinzani




# PET-adapted sequential salvage: BV as initial salvage




BV is an effective bridge to ASCT, some pts can avoid chemo

- MSKCC study (n = 65)
  - 28% DS 1-2 direct to ASCT
  - 75% DS 1-2 after BV +/- ICE
  - 64/65 proceeded to ASCT

- COH study (n = 56)
  - 50% direct to ASCT after BV
  - 50/56 proceeded to ASCT
  - 2y PFS 67% overall
  - 2y PFS 77% after BV alone



# BV + ICE




Etoposide: 100 mg/m<sup>2</sup> IV on Days 1, 2, and 3


K Cityof Hope.

Cassaday et al ASH 2016 #1834

# BV + DHAP (BRaVE study)




Gr 3-4 Toxicities 63% neutropenia, 30% F&N 81% thrombocytopenia Hagenbeek A et al. ASH 2018




### Extended follow up from BrESHAP first salvage study demonstrates most patients still in remission at 3 years

- Combination of BV and ESHAP chemotherapy [BRESHAP] as 2<sup>nd</sup> line therapy for RRHL prior to ASCT
- All but two pts (64/66) underwent stem cell mobilization
- 61 pts were transplanted directly after BRESHAP salvage
- 50 patients received BV consolidation after transplant



Garcia-Sanz, Abstract #S113 EHA 2018

#### Immunotherapy for Malignant Lymphoma: 2019



Extended exposure and resistance to Bendamustine in HL cells is associated to a stable upregulation of CD30 and increased sensitivity to Brentuximab Vedotin

#### Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial



Lancet Oncol 2018; 19: 257-66

Owen A O'Connor, Jennifer K Lue, Ahmed Sawas, Jennifer E Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence Schwartz, Bin Cheng, Kerry J Savage, Diego Villa, Michael Crump, Anca Prica, Vishal Kukreti, Serge Cremers, Joseph M Connors, John Kuruvilla

	Phase 1 (n=28)	Phase 2 (n=37)	Total (n=65)
Overall response	17 (61% [41-79])	29 (78% [62-91])	46 (71% [58-81])
Complete response	5 (18%)	16 (43%)	21 (32%)
Partial response*	12 (43%)	13 (35%)	25 (38%)
Stable disease	4 (14%)	5 (14%)	9 (14%)
Not assessable	1(4%)	0	1 (2%)
Progression of disease	6 (21%)	3 (8%)	9 (14%)

Data are n (% [95% CI]) or n (%). "The patient with anaplastic large-T-cell lymphoma had a partial response in phase 1.

Table 2: Treatment response by study phase to brentuximab vedotin plus bendamustine





Figure 2: Responses to brentuximab vedotin plus bendamustine by study phase All complete remissions are defined by functional imaging as PET negative. One patient in phase 1 was not assessed radiologically because of a protocol violation in cycle 1.



Median PFS: 7.5 months (95% CI 4.8-12.1)

#### CLINICAL TRIALS AND OBSERVATIONS


#### Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce,<sup>1</sup> R. Gregory Bociek,<sup>2</sup> Ahmed Sawas,<sup>3</sup> Paolo Caimi,<sup>4</sup> Edward Agura,<sup>5</sup> Jeffrey Matous,<sup>4</sup> Stephen M. Ansell,<sup>7</sup> Howland E. Crosswell,<sup>6</sup> Miguel Islas-Ohlmayer,<sup>9</sup> Caroline Behler,<sup>16</sup> Eric Cheung,<sup>11</sup> Andres Forero-Torres,<sup>12</sup> Julie Vose,<sup>2</sup> Owen A. O'Connor,<sup>8</sup> Neil Josephson,<sup>13</sup> Yinghui Wang,<sup>13</sup> and Ranjana Advani<sup>24</sup>

#### Table 2. Best response on combination therapy

	Best clinical response, n (%) (95% CI)						
Population	CR .	PR	50	PD	ORR*		
Overal, N = 53	39 (73.6) (59.7, 64.7)	10 (18.9)	3(5.7)	1 (1.9)	49 (92.5) (01.8, 97.9)		
Response to frontline therapy Primary refractory, n = 28 Relapsed, n = 25	18 (64.3) [44.1, 81.4] 21 (84.0) [82.9, 95.5]	6 (21.4) 4 (16.0)	3 (10.7) 0 (0.0)	1 (3.4) 0 (0.0)	24 (85.7) (67.2, 96.0) 25 (100) (86.3, 100)		
<b>ASCT</b> Yes, π = 40 No, π = 13	3H (85.0) [70.2, 94.3] 5 (38.9) [13.9, 68.4]	4 (10.0) 6 (46.2)	2.6.8 1.9.7)	0-(0.0) 1 (7.7)	38 (95.0) (83.1, 99.4) 11 (84.6) (54.6, 98.1)		

97% 1<sup>st</sup> stem cell mobilization attempt success




#### ARTICLE


#### **Open Access**

#### First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi


A. Broccoli<sup>1</sup>, L. Argnani<sup>1</sup>, B. Botto<sup>2</sup>, P. Corradini <sup>1</sup>/<sub>O</sub><sup>1</sup>, A. Pinto<sup>4</sup>, A. Re<sup>5</sup>, U. Vitolo<sup>2</sup>, S. Fanti<sup>6</sup>, V. Stefoni<sup>1</sup> and P. L. Zinzani<sup>1</sup>, on behalf of Fondazione Italiana Linforni ONLUS



- ORR: 84.2%.
- CMR: 78.9%
- PR: 5.3%
- **Primary refractory**: ORR 75.0%
- **Relapsed:** ORR 94.4%
- 35 pts. successful mobilization
- 33 underwent ASCT



#### Median FU 23 mo.s



10

n

20


months


30

40


	Taxicity		Patients involved, N	Events, N	Overall frequency (%)	Grade 1, N	Grade 2, N	Grade 3, N	Grade 4, N
	Hematological tox	city	14	4)	100	16	7	15	1
	Neutropenia			13	31.7		2		3
	Leukopenia		6	12	293	2	4	6	
	Anemia			*	195	7	ж.		
	Thrombocytope		5	,	121	,			
	Febrie neutrop Extrahematologica		1	nddi	2.4	87	69	10	0
	Slin rection	1 JORO W	26	46	277	19	21	6	53 - E
	Fever		17	26	15.7	18	7	1	
ematolo oxicity G	the second se	N; ty	pe		n-hematologi icity Grade	ic	N; typ	e	
r 1-2		21		Gr	1-2		133		
ir 3		15; n	eutropenia	Gr 3	3		9; 5 sk	in react	tion, 1 IR
r 4			utropenia	Gr 4	1		0		
N. pt	ts								
N. pr 40 30	,				0		-		
40	, 				0			<b>e</b> gra	ide IV
40 30 20			3						ide IV v grad
40 30			3						
40 30 20			3						
40 30 20 10			3 14 atologica						

Broccoli et al. Blood Cancer Journal (2019)9:100







Herrera AF, et al. Blood 2018; Advani R et al. ASH 2018




PFS after BV+Nivo as 1st salvage therapy for HL



# Ibrutinib in Refractory Classic Hodgkin's Lymphoma



Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients With Relapsed/Refractory Hodgkin Lymphoma



\*Patients will be treated until disease progression, unacceptable toxicity, or moving onto auto- or allo-HCT \*\*Once PET portion is negative, it does not need to be performed again.

\*\*\*Subjects will be followed for up to two years with q3 month interval visits or telephone calls.

Characteristic, n (%)	Phase II Patients [n = 13] 560 mg Ibrutinib		
Gender			
Female	5 (38)		
Male	8 (62)		
Age	33 (17-69)		
Stage at Diagnosis			
1-11	7 (54)		
III-IV	6 (46)		
B symptoms (at diagnosis)	6 (46)		
Prior Therapy			
ABVD	12 (92)		
BEACOPP	3 (23)		
R-CHOP	1 (8)		
IGEV	1 (8)		
BV	1 (8)		
ICE	0		
Clinical Trials	0		
PD1 inhibitors	0		
Prior Radiation	3 (23)		
Status Prior to Treatment			
Progressive Disease	7 (54)		
Relapsed Disease	6 (46)		
Stable Disease	0		
Best Response to Induction			
Refractory	5 (38)		
Relapsed	8 (62)		

Characteristic, n (%)	Phase II Patients [n = 13] 560 mg Ibrutinib
Median Number of Cycles	5 (2-9)
Best Response	
CR	6 (46)
PR	5 (39)
SD	2 (15)
PD	0
Response Rate (PR/CR)	84.6%

Chen R, et al. Blood. 2017;130: Abstract 738.

n	% PET Negative	ASCT, n (%)	PFS/EFS (ITT)	PFS/EFS (Transplanted Patients)
65	83; 27 (BV alone)	64 (98)	82% at 3 years	NR
56	66; 43 (BV alone)	50 (89)	NR	67% at 2 years
55	74	40 (72)	62.6% at 2 years	69.8% at 2 years
59	73	43 (73)	62.2% at 2 years	80.8% at 2 years
42	67	34 (76)	NR	NR
24	87	19 (79)	NR	NR
61	79	53 (87)	76% at 2 years	NR
66	70	60 (91)	71% at 30 months	NR
62	61	42 (68) after only BV-nivolumab; 14 (23) after additional salvage	82% at 21 months	97% at 21 months for patients transplanted after only BV-nivolumab
	n 65 56 55 59 42 24 61 66	n         % PET Negative           65         83; 27 (BV alone)           56         66; 43 (BV alone)           55         74           59         73           42         67           24         87           61         79           66         70	n         % PET Negative         ASCT, n (%)           66         83; 27 (BV alone)         64 (98)           56         66; 43 (BV alone)         50 (89)           55         74         40 (72)           59         73         43 (73)           42         67         34 (76)           24         87         19 (79)           61         79         53 (87)           62         61         42 (68) after only BV-nivolumab;	n       % PET Negative       ASCT, n (%)       PFS/EFS (ITT)         65       83; 27 (BV alone)       64 (98)       82% at 3 years         56       66; 43 (BV alone)       50 (89)       NR         55       74       40 (72)       62.6% at 2 years         59       73       43 (73)       62.2% at 2 years         42       67       34 (76)       NR         24       87       19 (79)       NR         61       79       53 (87)       76% at 2 years         66       70       60 (91)       71% at 30 months         62       61       42 (68) after only BV-nivolumab;       82% at 21 months

and the second s

TABLE 1. Newer Salvage Regimens for Relapsed or Refractory Hodgkin Lymphoma

# Brentuximab vedotin for newly diagnosed advanced HL

- Elderly
  - Single agent BV
  - Sequential BV and AVD
  - BV plus DTIC (Bendamustine ?)
  - BV plus Bendamustine (HALO)
  - BV plus Lenalidomide
  - BV plus combination CT (CAP: CTX,Doxo, Pred)
- Young
  - A2VD (ECHELON-1)
  - A-A2VD Nonbulky stage I/II HL
  - BrECADD

#### **BV-based combinations for upfront treatment of HL**

CLINICAL TRIALS AND OBSERVATIONS


Blood. 2017;130(26):2829-2837

# Frontline brentuximab vedotin in combination with datarbazine or bendamustine in patients aged $\geq 60$ years with HL

Jonathan W. Friedberg,<sup>1</sup> Andres Forero-Torres,<sup>2</sup> Rodolfo E. Bordoni,<sup>3</sup> Vivian J. M. Cline,<sup>4</sup> Dipti Patel Donnelly,<sup>5</sup> Patrick J. Flynn,<sup>6</sup> Gregg Olsen,<sup>7</sup> Robert Chen,<sup>8</sup> Abraham Fong,<sup>9</sup> Yinghui Wang,<sup>9</sup> and Christopher A. Yasenchak<sup>10</sup>


#### Table 3. Summary of best clinical response

BV+DTIC (n = 21)	BV+bendamustine (n = 17)
21 (100)	17 (100)
83.9, 100	80.5, 100
13 (62)	15 (88)
8 (38)	2 (12)
38.4, 81.9	63.6, 98.5
	21 (100) 83.9, 100 13 (62) 8 (38)



#### Table 4. Summary of AEs

	BV+DTIC (n = 22)	BV+bendamustine (n = 20)
Any TEAE*	22 (100)	20 (100)
Treatment-related AEs	22 (100)	19 (95)
Grade ≥3 AEs	10 (45)	18 (90)
SAEs	4 (18)	13 (65)
AEs leading to treatment discontinuation	12 (55)	12 (60)
Deaths within 30 d of last dose	0	2 (10)†



# Brentuximab vedotin for newly diagnosed advanced HL

#### **BV Alone or in Combination (DTIC) for Elderly Patients with untreated HL**


- Long-term follow-up of brentuximab vedotin \*/- dacarbazine as first line therapy in elderly patients with HL has shown to induce long-term remissions for a subset of patients
- BV + dacarbazine may be an induction option for frail, elderly patients ineligible for standard treatment with durable responses leading to a 3-year overall survival rate of 90% with combination therapy.
- Median observation time from first dose (time to death or last contact)
  - BV: 42.6 months (range, 4.6–56.3)
  - BV+DTIC: 37.8 months (range, 14.8–44.8)

-Disclosuments weaklow in it implies 77.		BV (N = 27)	BV+DTIC (N = 22)
Contraction and the second	3-yr PFS rate (95% CI)	34% (16%, 53%)	52% (26%, 73%)
Conservation and an annual of	3-yr OS rate (95% CI)	71% (49%, 85%)	90% (65%, 97%)
(Day Toop to Microsee	Tx-emergent PN, n (%)	24 (89%)	19 (86%)
DDC XIS excited N	Complete resolution, n/N (%)	9/24 (38%)	5/19 (26%)
(Day 1) up to 12 cycles	Some resolution/improvement, n/N (%)	9/24 (38%)	8/19 (42%)
	Renetational and the 1.1 mphy IV (Day Town to Mingdow) DRC 375 mg/mf IV	IDex Houses Microsom         Bimiliants Microsom         Bimiliants Microsom         Diff: 375 mg/ml N	Date list to Microsoft         EV (N = 27)           3-yr PFS rate (95% CI)         34% (16%, 53%)           3-yr OS rate (95% CI)         71% (49%, 85%)           DTIC 375 egter N         Complete resolution, n/N (%)         9/24 (38%)

#### Sequential Cohorts

a 3-week system


b If a patient had clinical kenefit per the investigator, continued BV Vestiment beyond 18 cycles was allowed until disease progression or famicity.



Adding DTIC to BV monotherapy may increase durability of response and survival in the elderly population

Friedberg al al, ASCO 2018, Poster #179, Abstract #7542

 Phase 2 study of untreated older HL patients received 2 doses of BV followed by 6 cycles of AVD: responding pts received 4 BV consolidation doses.



ITT median follow-up 23 mos – 2 yr PFS 84%

- 2yr OS 95%

In this elderly population, the following prognostic factors were associated with significantly inferior PFS


- High Cumulative Illness Rating Scale-Geriatric (CIRS-G)co-morbidity score (p<0.0001)</li>
- loss of instrumental activities of daily living (iADL) (p<0.0001)</li>

# HALO STUDY: Phase 1/2 Trial of BV + Bendamustine in Elderly Pts. (n= 51) With Advanced HL

Objective: Phase I: Tolerability and toxicity (n=12); Phase II: Response rate after completion of treatment (n=48) Patients: elderly pts with advanced classical HL

Dose and schedule: Brentuximab vedotin 1.2 mg/kg IV over 30 minutes on days 1 plus bendamustine 90 mg/m<sup>2</sup>

IV over 30-60 minutes on days 1 and 2, Q3wk




#### HALO STUDY: Phase 1/2 Trial of BV + Bendamustine in Elderly Pts. With Advanced HL

RESPONSES			
	Evaluated	treatment cycle	
Deauville score	Cycle 2 (n=51)	<b>Treatment Response</b>	End of TRT (n=51)
1-3	40 (78%)	CR (score 1-3)	32 (63%)
4	6 (12%)	PR (score 4)	2 (4%)
5	2 (4%)	NR/Pro	10 (19%)
NE	3* (6%)	NE	7**(14%)


<u>+</u>	icities grade > 3 (n=108)
91 (58.5%)	lymphocytopenia
33 (21%)	WBC decreased
5 (3%)	Rash/Infusion reaction/Device Infection
5 (3%)	CMV reactivation
3 (2%)	Febrile neutropenia
2(1.5%)	Stomatitis
1 (0.5%)	Thrombocytopenia
15 (10.5%)	Other( ALAT increased, GGT increased, Hypersensitivity, Pyrexia, Rash maculo-papular)

(SN) Safety:

- Toxicities grade 3-4 : No platelet or erythrocyte cells transfusion were required during treatment
- No neuropathy recorded
   ≥ grade 3



#### Progression Free Survival: Intention to treat




- 6/51 (10%) pts died: recurrent HL (3), CMV reactivation (2), 2nd neoplasm (1)
- Median follow-up of 22 (0-30) months: 31/51 (63%) pts in continuous CR in PP analysis

#### Conclusions

The present analysis, though conducted in 85% of enrolled patients, showed that Be-BV is an effective regimen in the real life of elderly HL, when delivered according to the schedule.

The toxicity of this treatment could be improved by a more strict prophylaxis of CMV infections,



#### CLINICAL TRIALS AND OBSERVATIONS

#### Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Jeremy S. Abramson,<sup>1</sup> Jon E. Arnason,<sup>2</sup> Ann S. LaCasce,<sup>3</sup> Robert Redd,<sup>3</sup> Jeffrey A. Barnes,<sup>1</sup> Lubomir Sokol,<sup>4</sup> Robin Joyce,<sup>2</sup> David Avigan,<sup>2</sup> Donna Neuberg,<sup>3</sup> Ronald W. Takvorian,<sup>1</sup> Ephraim P. Hochberg,<sup>1</sup> and Celeste M. Bello<sup>4</sup>

#### Table 1. Patient characteristics (N = 34)

Characteristic	
Age, median (range), y	36 (20-75)
Female/male	17/17
Stage	
IA	6 (18%)
ILA	24 (71%)
IIB	4 (12%)
Size of largest lesion, median trangel, cm	3.34 (1.51-8.33
Risk	
Early favorable	21 (62%)
Early unfavorable	13 (38%)
Histology	
Nodular sclerosis	18 (53%)
Mixed cellularity	4 (12%)
Lymphocyte-rich	4 (12%)
Classical not otherwise specified	8 (24%)

#### Table 2. Response (N = 34)

Dose reductions: 38% of pts.
(periph. sens. neuropathy)
All grade neuropathy: 79%

- Grade 3/4 toxicities:
  - Neutropenia (62%)
  - Febr. neutropenia (35%)
  - Neuropathy (24%)
- 1 Neutropenic death (1° course)

#### KEY POINTS

- Brentuximab vedotin plus AVD without consolidative radiation is an effective therapy for nonbulky limitedstage HL.
- Peripheral neuropathy and neutropenic fever appear increased with brentuximab-AVD compared with the expected toxicities of ABVD alone.

Time point	Overall response	CR	Partial response	Progressive disease	Not evaluable*
Monotherapy lead-in	34 (100; 89.7-100)	18 (52.9; 35.1-70.2)	16 (47.1; 29.8-64.9)	0 (0; 0-10.3)	0 (0; 0-10.3)
Cycle 2	33 (97.1; 84.7-99.9)	33 (97.1; 84.7-99.9)	0 (0; 0-10.3)	0 (0; 0-10.3)	1 (2.9; 0.1-15.3)
End of treatment	31 (91.2; 76.3-98.1)	31 (91.2; 76.3-98.1)	0 (0; 0-10.3)	1 (2.9; 0.1-15.3)	2 (5.9; 0.7-19.7)

Blood. 2019;134(7):606-613

# Brentuximab Vedotin: upfront treatment of HL

#### Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma


Joseph M. Connors,<sup>1</sup> Stephen M. Ansell,<sup>2</sup> Michelle Fanale,<sup>3</sup> Steven I. Park,<sup>4</sup> and Anas Younes<sup>5</sup>

	ABVD + brentuximab vedotin	AVD + brentuximab vedotin
n	25	26
Age, y, median (range)	35 (19-59)	33 (18-58)
Male sex, n (%)	20 (80)	17 (65)
Performance status," n (%)		
0	13 (52)	11 (42)
1	12 (48)	15 (58)
Stage, n (%)		
IIA bulkyt	0	3 (12)
IIB	4 (16)	4 (15)
IIIA	5 (20)	3 (12)
IVA	4 (16)	5 (19)
IVB	12 (48)	11 (42)
International Prognostic Score, n (%)		
0-3	5 (20)	12 (46)
4-7	20 (80)	14 (54)


\*Eastern Cooperative Oncology Group scale. †Bulky – any mass ≥10 cm.

Table 4 Datient observiction

CR: 96% 5-year FFS: 92% 5-year OS: 100%



# ECHELON-1: A+AVD versus ABVD in advanced stage HL




Primary endpoint: modified PFS per IRF, with an event defined by the first evidence of:

- Disease progression, or
- Death, or


 Evidence of non-complete response (PET scan Deauville score 3–5) after completion of frontline therapy, followed by subsequent anticancer therapy. . Connors JM, et al. N Engl J Med 2018;378:331-44.

# **Echelon-1: BV improves modified PFS**



Connors et al. NEJM online 2017

 A+AVD vs ABVD resulted in a 30% reduction in the risk of progression or death at 3 years




# **Echelon-1: Who benefits from addition of BV?**


Subgroup	Event A+AVD	/ N (%) ABVD		Hazard ratio (95% CI)
Overall	117/664 (17.6)	146/670 (21.8)		0.77 (0.60-0.98)
Age <60 years	93/580 (16.0)	117/568 (20.6)	H 44	0.73 (0.56-0.96)
Age 260 years	24/84 (28.6)	29/102 (28.4)		1.01 (0.59-1.73)
Age <45 years	70/451 (15.5)	83/423 (19.6)		0.73 (0.53-1.01)
Age ≥45 years	47/213 (22.1)	63/247 (25.5)		0.86 (0.59-1.26)
Region: Americas	41/261 (15.7)	58/262 (22.1)		0.65 (0.44-0.97)
Region: North America	38/250 (15.2)	57/247 (23.1)		0.60 (0.39-0.90)
Region: Europe	62/333 (18.6)	74/336 (22.0)		0.83 (0.59-1.17)
Region: Asia	14/70 (20.0)	14/72 (19.4)		0.91 (0.43-1.93)
IPS: 0-1	22/141 (15.6)	25/141 (17.7)	· · · · ·	0.83 (0.47-1.48)
IPS: 3-3	57/354 (16.1)	68/351 (19.4)		0.79 (0.56-1.13)
IPS: 4-7	38/169 (22.5)	53/178 (29.8)		0.70 (0.46-1.07)
Stage III	40/237 (16.9)	43/246 (17.5)		0.92 (0.60-1.42)
Stage IV	77/425 (18.1)	102/421 (24.2)		0.71 (0.53-0.96)
B symptoms: Present	77/399 (19.3)	94/381 (24.7)		0.74 (0.55-1.01)
B symptoms: Absent	40/265 (15.1)	52/289 (18.0)		0.79 (0.52-1.20)
Extranodal sites: 0	40/217 (18.4)	39/228 (17.1)		1.04 (0.67-1.62)
Extranodal sites: 1	36/217 (16.6)	45/223 (20.2)		0.75 (0.48-1.16)
Extranodal sites: >1	39/194 (20.1)	57/193 (29.5)		0.67 (0.44-1.00)
Gender: Male	64/378 (16.9)	90/398 (22.6)		0.71 (0.51-0.97)
Gender: Female	53/286 (18.5)	56/272 (20.6)		0.86 (0.59-1.26)
		0.1	0.5 1 Hazard ratio	
Younger patients North American pts			Favors A+AVD Favors ABVD	
Extranodal sites > 1 Stage IV			Connors et al. NF.IM onli	ne 2017

Connors et al. NEJW online 2017


# Echelon-1: 1+ extranodal sites or stage IV disease



Summary of mPFS per IRF: High-risk sub-groups



# Echelon-1: Favorable outcomes after PET2+ with BV-AVD



PET2 neg 2-y mPFS BV-AVD 85 % ABVD 82 %


Impact of BV-AVD most notable in PET2+ pts

	PET2 pos 2-y mPFS
BV-AVD	58 %
ABVD	42 %


Courtesy Chen et al ASCO 2018 # 7539


# A2VD is more toxic than ABVD and requires G-CSF support

	BV+AVD	ABVD
Grade ≥3 AE	549 (83%)	343 (66%)
SAE	284 (43%)	178 (27%)
PN all grades	55%	30%
PN grade ≥ 3	9%	1%
SAE of febrile neutropenia, sepsis, infection, neutropenia	33% no G-CSF ppx 24% G-CSF ppx	17% no G-CSF ppx 9% G-CSF ppx




 PN continues to resolve and improve over time, with the majority of patients experiencing complete resolution





mPFS per IRF by baseline sCD30: ABVD arm 18 5.0 HP-0470 875-0 8321-6388 p-0301 344 34 -mar mer a Patents at Patients, 1 - Abda N (20) 3, 1965, [1] ---chevilsen für Molectili vCDN 20 約7(開车相信) 124 424 00008 Carporal -Muchan IS 38 网络综合理论 108 2 4 4 4 5 5 1 1 1 1 2 2 2 2 2 2 2 2 2 3 3 4 4 4 4 4 4 4 4 Time (months thread of Judiority of the --8.409 ...... A4 25 36 10 10 HE 14 HE \*\* -...... -. . . . -66

"If it states was reside undertailer





# Brentuximab Vedotin in the Overall Treatment Strategy for HL

	BrECAPP	BrECADD
Restaging after two cycles*	1 March 19	
OR	2/50 (4%)	0/52
CRu	4/50 (8%)	6/52 (12%)
PR	40/50 (80%)	45/52 (87%)
NC	4/50 (BK)	1/57 (2%)
PET after two cycles (Deauville score)		
1	13/49 (27%)	9/52 (17%)
2	7/49 (14%)	14/52 (27%)
3	18/49 (37%)	18/52 (35%)
4-5	11/49 (22%)	11/52 (21%)
Restaging after six cycles !		
CR	4/48 (8%)	3/52 (6%)
ORu	3/48 (6%)	7/52 (13%)
PR	1/48 (2%)	2/52 (4%)
PR (residual ≥2.5 cm)	40/48 (83%)	39/52 (75%)
PD (residual a 2-5cm)	0/48	1/52 (2%)
PET after chemotherapy (Deauville scor	e)‡	
1	10/40 (25%)	13/40 (33%)
2	9/40 (23%)	13/40 (33%)
3	14/40 (35%)	8/40 (20%)
4-5	7/40 (18%)	6/40 (15%)
Complete response to chemotherapy		
No (further treatment recommended by CREP)	7/49 (14%)	6/52 (12%)
Yes (CR or PR <2.5 cm [local investigator] or no indication for further treatment [CREP])	42/49 (86%)	46/52 (88%

Etoposide 1-3 200 150 200 1 35 40 35 Cyclophosphamide 2 1250 1250 1250 Vecristine 8 1.4 Brentusimab vectorin 1 1.8 1.6 Procarbazine 1-7 100 100 Prochisone 1-14 40 40 Dacarbazine 2-3 250 Desamethasone 1-4 40 0 0 0 0 0 0 0 0 0 0 0 0 0	Drug	Day	BEACOPP	BrECADD	BrECAPP
1         35         40         35           Cyckophosphamide         2         1250         1250         1250           Vincristine         8         1.4         1.8         1.8           Procarbazine         1-7         100         100           Procarbazine         2-3         230         200           Decarbazine         2-3         200         14         40           0         14         40         40         40	Bleomycin	8	10		
Cyclophosphamide         2         1250         1250         1250           Vincristine         8         1.4         1.8         1.8           Procarbazine         1-7         100         100           Procarbazine         2.3         250           Decarbazine         2.3         250           Decarbazine         1.4         40           0         40         40           0         95% (95% CI 85–100) BrECAPP         89% (95% CI 77–100) BrECADD           0         0         0         0           0         0         0         0         0           0         0         0         0         0         0	Etoposide	1-3	200	150	200
Vincristine Brentusimab vedicin Procatizatine 1-7 100 100 Produisone 1-4 40 Decarbazine 2-3 2-3 2-30 Decarbazine 1-4 40 40 40 40 40 40 40 40 40 4		1	35	40	35
Brentuzimab vedotin 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Cyclophosphamide	2	1250	1250	1250
Procarbazine 1-7 100 100 Prechrizone 1-14 40 40 Dacarbazine 2-3 250 Decarmethasone 1-4 40 1-14 40 Decarbazine 2-3 250 Decarmethasone 1-4 40 1-14 40	Vincristine	8	1.4		
Predhisone 1-14 40 40 Decarbazine 2-3 250 Decarmethasone 1-4 40	Brentusimab vedotin	1		1.8	1.8
Dacarbazine 23 250 Decamethasone 14 40	Procarbazine	1.7	100		100
Desamethasone 14 40	Prechisone	1-14	40		40
18-mo.s PFS           95% (95% CI 85–100) BrECAPP           89% (95% CI 77–100) BrECADD	Dacarbazine	23		250	
18-mo.s PFS           95% (95% CI 85–100) BrECAPP           89% (95% CI 77–100) BrECADD	Desamethasone	1-4		40	
10- 10- 0- 0- 0- 0- 12- 12- 12- 12- 12- 12- 12- 12	100	-	-1-1-4-6-6		
	90-	95% (9	95% CI 85-		
	90-	95% (9	9	5% CI 85-	5% CI 85–100) BrECA
k Time since randomitation (months)	90- 80- 70- 60- 50- 40- 30- 10- 10- BrtCAPI	95% (9 89% (9	95% CI 85– 95% CI 77–	100) BrECA	
BrECAPP 49 (0) 49 (0) 37 (12) 18 (30)	90- 80- 70- 60- 50- 40- 10- 10- Bit(API Bit(API	95% (9 89% (9	95% CI 85– 95% CI 77–	100) BrECA	<b>NDD</b>


# Brentuximab Vedotin in the Overall Treatment Strategy for HL






# ... Novel Agents for cHL: Operating Instructions

S1826: A Phase III Randomized Trial of Nivolumab Plus AVD in Patients (Age ≥ 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma



# Brentuximab Vedotin in the Overall Treatment Strategy for HL



# ... Novel Agents for cHL: Checkpoint Inhibitors

### 3. CPIs are effective (ORR) regardless of disease chemorefractoriness

#### CheckMate 205: Response According to Refractory Status

	Primary refractory n = 142	Refractory to last line n = 114	Refractory to BV after auto-HSCT n = 70
Objective response, %	73	68	69
Best overall response, %			
Complete remission	18	13	6
Partial remission	55	54	63
Median DOR in patients with PR, months (95% CI)	13 (9, 18)	17 (9, NE)	17 (8, NE)ª

#### ORR to Pembrolizumab by Blinded C Review: Subgroup Analyses

Primary Refractory Disease (n = 73)		Relapsed After ≥3 Lines of Therapy (n = 146)		
n (%)	95% CI <sup>‡</sup>	n (%)	95% CI‡	
58 (79.5)	68.4-88.0	99 (67.8)	59.6-75.3	
17 (23.3)	14.2-34.6	31 (21.2)	14.9-28.8	
41 (56.2)	44.1-67.8	68 (46.6)	38.3-55.0	
4 (5.5)	1.5-13.4	24 (16.4)	10.8-23.5	
8 (11.0)	4.9-20.5	20 (13.7)	8.6-20.4	
3 (4.1)	0.9-11.5	3 (2.1)	0.4-5.9	
	(n n (%) 58 (79.5) 17 (23.3) 41 (56.2) 4 (5.5) 8 (11.0)	(n = 73)       n (%)     95% Cl <sup>2</sup> 58 (79.5)     68.4-88.0       17 (23.3)     14.2-34.6       41 (56.2)     44.1-67.8       4 (5.5)     1.5-13.4       8 (11.0)     4.9-20.5	(n = 73)     (n       n (%)     95% Cl <sup>‡</sup> n (%)       58 (79.5)     68.4-88.0     99 (67.8)       17 (23.3)     14.2-34.6     31 (21.2)       41 (56.2)     44.1-67.8     68 (46.6)       4 (5.5)     1.5-13.4     24 (16.4)       8 (11.0)     4.9-20.5     20 (13.7)	


\*Based on binomial exact confidence interval method

Zinzani, 14-ICML


# ... Novel Agents for cHL: Checkpoint Inhibitors

### **Putative Mechanism of Resistance: not known**

1. More CR and longer PFS observed with higher degrees of PD-L1 expression




2. More CR and longer PFS observed with higher degrees of HLA-DR expression



# Failure of primary chemotherapy for advanced HL

# BV ± PET-Adapted Sequential AuglCE Prior to ASCT for R/R HL



\*For pts with weight > 100 kg, dosing calculated with upper limit of 100 kg. In pts with grade 2 neuropathy, BV dose reduced to 0.8 mg/kg; with grade 3 neuropathy, BV discontinued. \*AugICE consisted of 2 doses ifosfamide 5000 mg/m<sup>2</sup> + unprotective agent mesna 5000 mg/m<sup>2</sup> IV on Days 1-2; 3 doses of etoposide 200 mg/m<sup>2</sup> IV Q12H beginning on Day 1; carboplatin at AUC of 5 (max. 800 mg) on Day 3.

Overall 76% achieved PET- status and proceeded to HDT/ASCT

Moskowitz AJ, et al. Lancet Oncol. 2015;16:284-292.

# **RR-HL: Effect of Pre-Transplant (ASCT) PET assessment**


Strategies to achieve a PET neg.ve status @ transplant:

- Sequential single agent BV and chemotherapy (...on demand...)
  - BV alone (about 30-35% of pts. achieve a metabolic CR)
  - BV <mCR: ICE, DICE, IGEV, GVD, GDP
  - BV and Bendamustine or Bendamustine and BV
- Incorporate BV into salvage
  - Bendamustine BV (BBV)
  - BV-DHAP (Brave)
  - BV-ESHAP (BrESHAP)
  - BV-ICE

# Change 'conventional' salvage platform

- BeGEV
- Test a 'chemo-free' strategy (BV+CPI)

# ... Novel Agents for cHL: Operating Instructions



... Novel Agents for cHL: Operating Instructions


# BV + Nivolumab is an effective 2<sup>nd</sup> line therapy and bridge to transplant

80


60

87% ORR, 68% CR among efficacy evaluable patients (n=90)

(85% ORR, 66% CR among all treated patients, n=91)



## ...Novel Agents for cHL: Operating Instructions



# **Immunotherapy Lymphoma 2019**



Dolabella auricularia, la miglior soluzione contro qualsiasi tipo di alga, anche quelle più ostili come l'alga briopsis. Instancabile divoratrice di qualsiasi alga infestante possiate trovarvi in acquario.

# €22.90





# ...Novel Agents for cHL: Operating Instructions


### **Brief Report**

#### 🔇 blood

#### CLINICAL TRIALS AND OBSERVATIONS


#### Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen,<sup>1,\*</sup> Ajay K. Gopal,<sup>2,\*</sup> Soott E. Smith,<sup>3</sup> Stephen M. Ansell,<sup>4</sup> Joseph D. Rosenblatt,<sup>8</sup> Kerry J. Savage,<sup>6</sup> Joseph M. Connors,<sup>6</sup> Andreas Engert,<sup>7</sup> Emily K. Larsen,<sup>8</sup> Dirk Huebner,<sup>9</sup> Abraham Fong,<sup>8</sup> and Anas Younes<sup>10</sup>




For patients in CR, the estimated 5-years OS rate was 64% and PFS was 52%

# **Overall Treatment Strategy for (adv. HL): a moving target**




# Brentuximab vedotin for RR-HL: one, no one, one-hundred-thousand

# **BV + ESHAP (BRESHAP)**




Garcia-Sanz et al. Ann Oncol 2019

# Hodgkin Lymphoma: defining Hi-Risk Patients




# Brentuximab vedotin for RR-HL: one, no one, one-hundred-thousand



Broccoli et al. Blood Cancer Journal (2019)9:100 CW cytomegalovinus, ALT alanine transminase, AST aspartic transminase, gamma-GT gamma glutar

# Failure of primary chemotherapy for advanced HL

# Salvage BV ± PET-Adapted Physician's Choice of CT Prior to ASCT



Chen R, et al. Biol Blood Marrow Transplant. 2015;21:2136-2140.

# **RR-HL: Effect of Pre-Transplant (ASCT) PET assessment**

1. Works


## 2. Works rapidly

# 3. Synergizes with BV

Parameter			No.	CR (%	ó)	PR (%)	ORR (%)
Response (all			36	12(33)		7 (19)	19 (53)
Response to I	ast F	ξx					
Sensitive			16	9 (56)		2 (13)	11 (69)
Resistant			18	3 (17)		5 (28)	8 (45)
Reference	n	Dose		ORR	CR	Prior R>	(
Corazzelli	41	90-120 mg days 1 & 2, 4 wks		58%	31%		
Ghesquieres	28	90-120 mg/m2, days 1 & 2, every 4 wks		50%	29%	1	
Anastasia	67	90-120 mg/m2, days 1 &2, every 4 wks		57%	25%	67% failed 33% failed	d auto SCT d allo SCT
Zinzani	27	90 ma/m2		56%	37%	All receive	ed prior BV


days 1 & 2, every 4

wks



2-4 courses to best resp.

# HDLM2 L428 L540 KMH2 L1236 R25 R50 R75 R100



Moskowitz AJ, Hamlin PA, Perales MA, et al. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. <u>J Clin Oncol.</u> 2013 Feb 1;31(4):456-6c Corazzelli, et al. British Journal of Haematology, 2013;160:207-215 Ghesquieres, et al. Leukemia & Lymphoma, 2013;54(11):2399-2404 Anastasia, et al. British Journal of Haematology, 2014;166:140-153 Zinzani, et al. Clinical Lymphoma, Myeloma & Leukemia, 2015;15(7):404-408

56% refractory to BV


De Filippi et al. ASH 2015 Leoni et al. ASH 2003

# Brentuximab Vedotin-based combinations for RR-HL

CLINICAL TRIALS AND OBSERVATIONS


#### Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Alex F. Herrera,<sup>1</sup> Alison J. Moskowitz,<sup>2</sup> Nancy L. Bartlett,<sup>3</sup> Julie M. Vose,<sup>4</sup> Radhakrishnan Ramchandren,<sup>5</sup> Tatyana A. Feldman,<sup>6</sup> Ann S. LaCasce,<sup>7</sup> Stephen M. Ansell,<sup>6</sup> Craig H. Moskowitz,<sup>2</sup> Keenan Fenton,<sup>9</sup> Carol Anne Ogden,<sup>9</sup> David Taft,<sup>9</sup> Qu Zhang,<sup>8</sup> Kazunobu Kato,<sup>10</sup> Mary Campbell,<sup>9</sup> and Ranjana H. Advani<sup>11</sup>




#### Table 1. Baseline demographics and disease characteristics

	n = 62
Age (y), median (range)	36 (18-69)
Sex, n (%)	
Male	30 (48)
Female	32 (52)
Disease stage at initial diagnosis, n (%)	2010/02/2010
INI	37 (60)
III/IV	24 (39)
Unknown	1 (2)



#### Resolution or improvement\* in PN events with continued follow-up



\*Resolution is defined as event outcome of 'resolved' or 'resolved with sequelae'. Improvement was defined as 'improved by ≥1 grade from worst grade as of the latest assessment'.
\*Total patients with PN.

#### Ongoing PN events at primary analysis and after 10 months additional follow-up\*

	A	AVD	ABVD	
	Primary analysis	Continued follow-up	Primary analysis	Continued follow-up
Patients with ongoing PN, n	251	182	112	81
Maximum severity grade 1, n (%)	160 (64)	106 (58)	80 (71)	53 (65)
Maximum severity grade 2, n (%)	72 (29)	58 (32)	28 (25)	24 (30)
Maximum severity grade 3, n (%)	18 (7)	17 (9)	4 (4)	4 (5)
Maximum severity grade 4, n (%)	1 (<1)	1 (<1)	0	0

\*Beyond 36 months follow-up was every 6 months.

Radford J, et al. ASH 2018, Poster presentation from Abstract #2921